Effective July 26, 2024, ODG by MCG is updating Appendix A − its drug formulary – with the following medication edits to both the preferred, first-line “Y” drugs, and drugs that are not recommended as a first-line treatment known as “N” drugs.
New “Y” drug added to Appendix A
Cambia® packet for oral solution, a new formulation of the non-steroidal anti-inflammatory drug (NSAID) diclofenac potassium has been added to Appendix A as a “Y” drug. Previously, Appendix A had only included diclofenac potassium tablets (as “Y” drugs) and capsules (as “N” drugs).
New “N” drugs added to Appendix A
Dual-ingredient combination products containing acetaminophen and butalbital are added as “N” drugs under the class of Migraine Products. Three-ingredient products containing butalbital, caffeine, and either acetaminophen or aspirin had already been included as “N” drugs.
Under Muscle Relaxants, two new dosage forms of baclofen are added as “N” drugs. Fleqsuvy® suspension and Lyvispah® granules join Ozobax® solution in this manner. Baclofen tablets remain on Appendix A as “Y” drugs.
The NSAID naproxen sodium ER, currently a “Y” drug, is set to change status to “N” drug. Other forms of naproxen and naproxen sodium will continue to be “Y” drugs.
“Y” drugs removed from Appendix A
Several NSAIDs are scheduled to be removed from Appendix A. These include diflunisal (Dolobid®), oxaprozin (Daypro®), piroxicam (Feldene®), and ketorolac (Toradol®) injections. Ketorolac nasal spray and tablets remain on Appendix A as “N” drugs.
Additionally, the brand example of Vivlodex® under meloxicam is removed. This leaves meloxicam tablets (Mobic®) as a “Y” drug.
The latest ODG updates also include minor changes to drug class names, generic availability, and brand name examples. For instance, the Appendix A had separate drug classes listed for Triptans, Calcitonin gene-related peptide (CGRP) Inhibitors, and Misc. Analgesics, but these have now been combined under Migraine Products.
About ODG
ODG by MCG offers highly configurable, industry-specific medical treatment and return-to-work solutions, which are used for managing workers’ compensation, disability, and auto liability claim outcomes with evidence-based, data-driven decision support.
MyMatrixx Actions
MyMatrixx maintains ODG-based formularies and will update them in accordance with the above changes. For any changes, please reach out to your MyMatrixx account team.